Shire in the hunt for promising new stem cell tech

The UK's Shire has been making a series of small-$3 million to $5 million-investments in stem cell developers as the CEO continues to hunt for viable new business opportunities. "The science is there," said Angus Russell, "the challenge is finding something you can turn into a business." Russell makes clear that he's taking a distinctly unsentimental approach to stem cell research, noting that he only wants to acquire technology that insurers will be willing to pay for. Report

Suggested Articles

Ironwood had once hyped this drug as a $2 billion-a-year asset, but IW-3718 has failed to live up to its high expectations.

Junshi’s PD-1 blocker is already approved in China for metastatic melanoma, but the Shanghai-based biotech may soon add throat cancer to its label.

The takeover will give Orgenesis control of an autologous cell therapy treatment for respiratory disease caused by COVID-19.